Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Benjamin Netanyahu delays judicial reforms after day of turmoil
    • China grants billions in bailouts as Belt and Road Initiative falters
    • Generative AI set to affect 300mn jobs across major economies
    • Pay transparency laws in US stir worker discontent
    • Top Fed official blasts SVB collapse as ‘textbook case of mismanagement’
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Saudi National Bank chair resigns following Credit Suisse comments
      • European ammunition maker says plant expansion hit by energy-guzzling TikTok site
      • First Citizens shares surge after Silicon Valley Bank deal
      • Tesla cars lose value faster than rival models after price cuts, data shows
      • Air India boss hails biggest turnround effort in airline’s history
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from March 27: Netanyahu delays judicial overhaul, First Citizens buys much of SVB
      • Top Fed official blasts SVB collapse as ‘textbook case of mismanagement’
      • Money market funds swell by more than $286bn amid deposit flight
      • Live news: Alibaba to split into 6 independent units
      • Crypto exchange Binance accused by CFTC of illegally serving US clients
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A new technology boom is at hand
      • China, Japan and the Ukraine war
      • Final salary pensions have been uniquely horrible for UK plc
      • We are all secretaries now
      • Why five days in the office don’t add up
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Matthew Desmond: ‘America does so much more to subsidise affluence than alleviate poverty’
      • Culture clash: the challenge of uniting fierce rivals UBS and Credit Suisse
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything I, an Italian, thought I knew about Italian food is wrong
      • My life with Ozempic – a weight-loss diary
      • The best black watches
      • Is France on the road to a Sixth Republic?
      • At LVMH, the legendary Gérald Genta brand is born again
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Antibiotic resistance

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 20 February, 2023
      Special ReportImpact Investing
      Impact funds help fight dementia and antibiotic resistance

      Some of the world’s biggest health challenges do not lend themselves to conventional investment

    • Wednesday, 8 February, 2023
      Special ReportFT Health: Future of Antibiotics
      Spread of antibiotic resistance revives interest in bacteria-killing viruses

      Experts believe bacteriophages could be crucial extra tool

    • Wednesday, 21 December, 2022
      Explainer
      Surge in infections leads to global shortage of antibiotics

      Manufacturers struggle to keep pace with post-pandemic demand as dozens of countries report low supply of drugs

    • Monday, 21 November, 2022
      Special ReportFT Health: Future of Antibiotics
      Tighter controls on antibiotics promise to curb drug-resistance

      Medicines are often given for viral infections such as flu, for which they are useless, but can cause side effects

    • Friday, 11 November, 2022
      Special ReportFT Health: Future of Antibiotics
      Pandemic holds back fight against antibiotic resistance

      Few countries have well funded plans to tackle health threat to millions

    • Thursday, 27 October, 2022
      Special ReportFT Health: Future of Antibiotics
      Drugmakers eye government money to combat antibiotic resistance

      Industry cautiously optimistic amid bipartisan support for US Pasteur bill

    • Monday, 24 October, 2022
      Special Report
      FT Health: Communicable Diseases

      Despite pledges to learn the lessons of Covid-19, caution is already waning. Plus: crisis turned a spotlight on healthcare services; climate change and urbanisation drive rise in ‘zoonotic’ illnesses; return of polio to US highlights impact of anti-vax campaigners

    • Wednesday, 7 September, 2022
      How ‘Fitbits for cows’ can tackle the antibiotic crisis

      Monitoring the health of cattle lowers the use of drugs — and the risk of bacterial resistance to them

    • Tuesday, 19 July, 2022
      Special ReportFT Health: Future of Antibiotics
      Antibiotic resistance raises prospect of untreatable gonorrhoea

      Just one drug remains effective for the sexually transmitted disease but soon the bacteria may be able to evade it

    • Tuesday, 19 July, 2022
      Special ReportFT Health: Future of Antibiotics
      India’s shrimp farms test antibiotic control

      Fast-growing food sector has become a test case for the use and abuse of the drugs

    • Tuesday, 19 July, 2022
      Special ReportFT Health: Future of Antibiotics
      Drug-resilient bacteria threat rises with spread of world’s war zones

      Infected wounds are growing cause for concern in the Middle East, Ukraine and beyond

    • Thursday, 26 May, 2022
      Special ReportFT Health: Future of Antibiotics
      Vaccines hold potential to curb antibiotic resistance

      Prevention is better than cure — but is too costly for some countries where drug-resistant bacteria are rampant

    • Thursday, 26 May, 2022
      Special ReportFT Health: Future of Antibiotics
      Diagnostic tests a crucial tool in fight against antibiotic resistance

      Identifying conditions can prevent inappropriate drug use, but there are barriers to progress in poorer regions

    • Monday, 18 April, 2022
      Lex
      Antibiotics: new incentives needed to fight superbugs Premium content

      Global co-operation is desperately needed to overcome threat from drug-resistant infections

    • Wednesday, 13 April, 2022
      Ramanan Laxminarayan
      Greater access to antibiotics is essential for curbing drug resistance

      Broader funding, registration and stewardship is pivotal to making the antibiotic market more sustainable

    • Wednesday, 13 April, 2022
      Special ReportFT Health: Future of Antibiotics
      Drug pollution in rivers raises risks of antibiotic resistance

      Study finds lower middle income countries in South Asia and Latin America have highest levels of pollutants

    • Tuesday, 12 April, 2022
      How will UK’s fixed-fee scheme for antibiotics help tackle the growing health crisis?

      Move could boost global development of drugs to ease antimicrobial resistance

    • Monday, 11 April, 2022
      UK launches world-first ‘subscription’ model for antibiotic supply

      Fixed fee aims to incentivise pharma groups to develop new drugs and curb overprescription

    • Monday, 7 March, 2022
      Special ReportFT Health: Future of Antibiotics
      Antibiotic resistance in Africa: ‘a pandemic that is already here’

      Drug-resistant pathogens and poor hygiene mean simple procedures can deteriorate into lengthy and costly infections

    • Monday, 7 March, 2022
      Special ReportFT Health: Future of Antibiotics
      How pharma economics hold back antibiotic development

      New drugs are needed as resistance grows but plans to improve incentives are too modest, executives say

    • Friday, 28 January, 2022
      Sally Davies
      It’s time to confront the pandemic of antibiotic resistance

      To save lives and economies, we must make progress by drawing on lessons from Covid-19

    • Thursday, 20 January, 2022
      Special ReportFT Health: Future of Antibiotics
      Antibiotic resistance kills over 1m people a year, says study

      Research underscores the dangers of bacteria developing the ability to resist drugs

    • Wednesday, 24 November, 2021
      Special ReportFT Health: Future of Antibiotics
      Antibiotic accountability: how countries and companies perform

      FT dashboard tracks responses to the growing threat of antimicrobial resistance

    • Friday, 19 November, 2021
      Special ReportFT Health: Future of Antibiotics
      Pressure grows for funding to tackle ‘silent pandemic’ of antimicrobial resistance

      Political will is needed to address absence of sufficient financial incentives for new drugs

    • Thursday, 18 November, 2021
      Special ReportFT Health: Future of Antibiotics
      Limited access to antibiotics is driving resistance, warns watchdog

      Failure to ensure they reach world’s poorest increases health risks, says pharma body

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In